Imperial Oil Limited Common Stock vs Sanofi SA — how do they compare? Imperial Oil Limited Common Stock trades at $130.2 (market cap $62.22B), while Sanofi SA trades at $40.51 (market cap $94.58B). The key difference: Sanofi SA is the larger of the two by market cap, and Sanofi SA pays the higher dividend (6.18%). Which is the better fit depends on your goals.
| IMO | SNY | |
|---|---|---|
Market Cap | $62.22B | $94.58B |
Volume | 560,544 | 3,988,460 |
Sector | Energy | Health |
52-Week High | $138.33 | $52.34 |
52-Week Low | $83.72 | $39.12 |
Enterprise Value | $63.13B | $113.80B |
Dividend Yield | 1.9% | 6.18% |
Typical Hold Time | — | 94 Days |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
SNY trades at $39.77, up 0.08% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21 versus $1.10 expected, and announced a significant expansion of its immunology alliance with Regeneron, valued up to $8 billion. Revenue for 2025 was $46.72 billion, with net income of $7.81 billion, reflecting a profit margin of 16.72%.
The outlook is mixed; recent collaborations and earnings beats provide growth catalysts, but a projected decline in 2026 net income to $4.0 billion and bearish technical indicators suggest near-term headwinds. Risks include execution of new partnerships and competitive pressures in the pharmaceutical sector.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Imperial Oil Limited is a Canadian integrated energy company that explores for and produces crude oil and natural gas, operates oil sands projects at Cold Lake, Kearl, and Syncrude, and refines and markets petroleum products under the Esso and Mobil brands. ExxonMobil Corporation holds a majority ownership stake in the company.
Read more on IMO →Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →